Molecular determinants of pentamidine-induced hERG trafficking inhibition

Molecular Pharmacology

Volumn 81, Issue 2, 2012, Pages 198-209

  Dennis, Adrienne T ^a   Wang, Lu ^a   Wan, Hanlin ^a   Nassal, Drew ^a,b   Deschenes, Isabelle ^a,b   Ficker, Eckhard ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; PENTAMIDINE; PHENYLALANINE; POTASSIUM CHANNEL HERG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BIOCHEMISTRY; CELL MIGRATION; DATA ANALYSIS; ELECTROPHYSIOLOGY; ENDOPLASMIC RETICULUM; HEART MUSCLE CELL; HUMAN; HUMAN CELL; MEDICAL RECORD; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; RAT;

ANTIPROTOZOAL AGENTS; BINDING SITES; ENDOPLASMIC RETICULUM; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LONG QT SYNDROME; MOLECULAR CHAPERONES; PENTAMIDINE; PROTEIN CONFORMATION; PROTEIN TRANSPORT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84862916799     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.075135     Document Type: Article

References (51)

1. Anderson CL, Delisle BP, Anson BD, Kilby JA, Will ML, Tester DJ, Gong Q, Zhou Z, Ackerman MJ, and January CT (2006) Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation 113: 365-373. (Pubitemid 43803197)
2. Barbey JT, Pezzullo JC, and Soignet SL (2003) Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21:3609-3615. (Pubitemid 46594053)
3. Bian JS, Cui J, Melman Y, and McDonald TV (2004) S641 contributes HERG K+channel inactivation. Cell Biochem Biophys 41:25-40.
4. Bibler MR, Chou TC, Toltzis RJ, and Wade PA (1988) Recurrent ventricular tachycardia due to pentamidine-induced cardiotoxicity. Chest 94:1303-1306. (Pubitemid 19002808)
5. Burchmore RJ, Ogbunude PO, Enanga B, and Barrett MP (2002) Chemotherapy of human African trypanosomiasis. Curr Pharm Des 8:256-267.
6. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, and Izzo NJ Jr (1998) HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA 95:2979-2984. (Pubitemid 28135840)
7. Cordes JS, Sun Z, Lloyd DB, Bradley JA, Opsahl AC, Tengowski MW, Chen X, and Zhou J (2005) Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol 145:15-23. (Pubitemid 40675544)
8. de Boer TP, Nalos L, Stary A, Kok B, Houtman MJ, Antoons G, van Veen TA, Beekman JD, de Groot BL, Opthof T, et al. (2010) The anti-protozoal drug pentamidine blocks KIR2.x-mediated inward rectifier current by entering the cytoplasmic pore region of the channel. Br J Pharmacol 159:1532-1541.
9. Dennis A, Wang L, Wan X, and Ficker E (2007) hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans 35:1060-1063. (Pubitemid 350206429)
10. Doyle DA, Morais Cabral J, Pfuetzner RA, Kuo A, Gulbis JM, Cohen SL, Chait BT, and MacKinnon R (1998) The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science 280:69-77. (Pubitemid 28169082)
11. Fernandez D, Ghanta A, Kauffman GW, and Sanguinetti MC (2004) Physicochemical features of the HERG channel drug binding site. J Biol Chem 279:10120-10127. (Pubitemid 38372616)
12. 2+-induced modification of human ether-à-go-go-related gene (hERG) channel activation. J Physiol 567:737-755.
13. Ficker E, Dennis A, Kuryshev Y, Wible BA, and Brown AM (2005) HERG channel trafficking. Novartis Found Symp 266:57-69.
14. Ficker E, Dennis AT, Obejero-Paz CA, Castaldo P, Taglialatela M, and Brown AM (2000) Retention in the endoplasmic reticulum as a mechanism of dominantnegative current suppression in human long QT syndrome. J Mol Cell Cardiol 32:2327-2337. (Pubitemid 32039783)
15. Ficker E, Dennis AT, Wang L, and Brown AM (2003) Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res 92:e87-100.
16. Ficker E, Jarolimek W, Kiehn J, Baumann A, and Brown AM (1998) Molecular determinants of dofetilide block of HERG K+ channels. Circ Res 82:386-395. (Pubitemid 28101196)
17. Ficker E, Kuryshev YA, Dennis AT, Obejero-Paz C, Wang L, Hawryluk P, Wible BA, and Brown AM (2004) Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66:33-44. (Pubitemid 38822085)
18. Ficker E, Obejero-Paz CA, Zhao S, and Brown AM (2002) The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. J Biol Chem 277:4989-4998. (Pubitemid 34968538)
19. Gang H and Zhang S (2006) Na+ permeation and block of hERG potassium channels. J Gen Physiol 128:55-71. (Pubitemid 43967551)
20. ***García-Ferreiro RE, Kerschensteiner D, Major F, Monje F,***Stühmer W, and Pardo LA (2004) Mechanism of block of hEag1 K+ channels by imipramine and astemizole. J Gen Physiol 124:301-317.
21. Girgis I, Gualberti J, Langan L, Malek S, Mustaciuolo V, Costantino T, and McGinn TG (1997) A prospective study of the effect of I.V. pentamidine therapy on ventricular arrhythmias and QTc prolongation in HIV-infected patients. Chest 112: 646-653. (Pubitemid 27410699)
22. Gong Q, Keeney DR, Molinari M, and Zhou Z (2005) Degradation of trafficking-defective long QT syndrome type II mutant channels by the ubiquitin-proteasome pathway. J Biol Chem 280:19419-19425. (Pubitemid 41379650)
23. Guo J, Li X, Shallow H, Xu J, Yang T, Massaeli H, Li W, Sun T, Pierce GN, and Zhang S (2011) Involvement of caveolin in probucol-induced reduction in hERG plasma-membrane expression. Mol Pharmacol 79:806-813.
24. Guo J, Massaeli H, Xu J, Jia Z, Wigle JT, Mesaeli N, and Zhang S (2009) Extracellular K+ concentration controls cell surface density of IKr in rabbit hearts and of the HERG channel in human cell lines. J Clin Invest 119:2745-2757.
25. Hishigaki H and Kuhara S (2011) hERGAPDbase: a database documenting hERG channel inhibitory potentials and APD-prolongation activities of chemical compounds. Database (Oxford) 2011:bar017.
26. Kannankeril P, Roden DM, and Darbar D (2010) Drug-induced long QT syndrome. Pharmacol Rev 62:760-781.
27. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, Brown AM, Kang J, Chen XL, Sawamura K, et al. (2005) Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312:316-323. (Pubitemid 40096484)
28. Massaeli H, Guo J, Xu J, and Zhang S (2010) Extracellular K+ is a prerequisite for the function and plasma membrane stability of HERG channels. Circ Res 106: 1072-1082.
29. Mitcheson JS, Chen J, Lin M, Culberson C, and Sanguinetti MC. (2000) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97:12329-12333.
30. Nacher M, Carme B, Sainte Marie D, Couppié P, Clyti E, Guibert P, and Pradinaud R (2001) Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol 95:331-336. (Pubitemid 32575486)
31. Obers S, Staudacher I, Ficker E, Dennis A, Koschny R, Erdal H, Bloehs R, Kisselbach J, Karle CA, Schweizer PA, et al. (2010) Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine. Naunyn Schmiedebergs Arch Pharmacol 381:385-400.
32. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Sahara N, et al. (2002) Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 16:617-622. (Pubitemid 34449742)
33. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Takeshita A, et al. (2000) Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 133:881-885.
34. Pollard CE, Abi Gerges N, Bridgland-Taylor MH, Easter A, Hammond TG, and Valentin JP (2010) An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol 159:12-21.
35. Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, Holzem KM, Delisle BP, Anson BD, Makielski JC, et al. (2006) Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 149:481-489. (Pubitemid 44658508)
36. Sands M, Kron MA, and Brown RB (1985) Pentamidine: a review. Rev Infect Dis 7:625-634.
37. Sanguinetti MC and Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440:463-469.
38. Soeiro MN, De Souza EM, Stephens CE, and Boykin DW (2005) Aromatic diamidines as antiparasitic agents. Expert Opin Investig Drugs 14:957-972. (Pubitemid 41131649)
39. Staudacher I, Wang L, Wan X, Obers S, Wenzel W, Tristram F, Koschny R, Staudacher K, Kisselbach J, Koelsch P, et al. (2011) hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine. Naunyn Schmiedebergs Arch Pharmacol 383:119-139.
40. Takemasa H, Nagatomo T, Abe H, Kawakami K, Igarashi T, Tsurugi T, Kabashima N, Tamura M, Okazaki M, Delisle BP, et al. (2008) Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome. Br J Pharmacol 153:439-447. (Pubitemid 351199008)
41. Thomsen MB, Matz J, Volders PG, and Vos MA (2006) Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacol Ther 112:150-170. (Pubitemid 44301487)
42. van der Heyden MA, Smits ME, and Vos MA (2008) Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon? Br J Pharmacol 153:406-409. (Pubitemid 351199028)
43. Wan X, Dennis AT, Obejero-Paz C, Overholt JL, Heredia-Moya J, Kirk KL, and Ficker E (2011) Oxidative inactivation of the lipid phosphatase phosphatase and tensin homolog on chromosome ten (PTEN) as a novel mechanism of acquired long QT syndrome. J Biol Chem 286:2843-2852.
44. Wang L, Dennis AT, Trieu P, Charron F, Ethier N, Hebert TE, Wan X, and Ficker E (2009) Intracellular potassium stabilizes human ether-à-go-go- related gene channels for export from endoplasmic reticulum. Mol Pharmacol 75:927-937.
45. Wang L, Wible BA, Wan X, and Ficker E (2007) Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J Pharmacol Exp Ther 320:525-534. (Pubitemid 46147930)
46. Warmke JW and Ganetzky B (1994) A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA 91:3438-3442. (Pubitemid 24130252)
47. Wharton JM, Demopulos PA, and Goldschlager N (1987) Torsade de pointes during administration of pentamidine isethionate. Am J Med 83:571-576.
48. Wible BA, Hawryluk P, Ficker E, Kuryshev YA, Kirsch G, and Brown AM (2005) HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods 52:136-145. (Pubitemid 41008637)
49. Wu ZY, Yu DJ, Soong TW, Dawe GS, and Bian JS(2011) Progesterone impairs human ether-a-go-go-related gene (HERG) trafficking by disruption of intracellular cholesterol homeostasis. J Biol Chem 286:22186-22194.
50. Zhang S (2006) Isolation and characterization of I(Kr) in cardiac myocytes by Cs+permeation. Am J Physiol Heart Circ Physiol 290:H1038-H1049.
51. +channels expressed in Xenopus oocytes reduces rectification by shifting the voltage dependence of inactivation. J Physiol 509:129-137.